---
annotations:
- type: Pathway Ontology
  value: phosphatidylinositol 3-kinase-Akt signaling pathway
- type: Pathway Ontology
  value: breast cancer pathway
- type: Pathway Ontology
  value: disease pathway
- type: Pathway Ontology
  value: Notch signaling pathway
- type: Disease Ontology
  value: cancer
- type: Pathway Ontology
  value: cancer pathway
authors:
- Khanspers
- Egonw
- IreneHemel
- MaintBot
- Fehrhart
communities:
- CPTAC
description: 'Breast cancer is the leading cause of cancer death among women worldwide.
  The vast majority of breast cancers are carcinomas that originate from cells lining
  the milk-forming ducts of the mammary gland.   The molecular subtypes of breast
  cancer, which are based on the presence or absence of hormone receptors (estrogen
  and progesterone subtypes) and human epidermal growth factor receptor-2 (HER2),
  include:  * Luminal A subtype: Hormone receptor positive (progesterone and estrogen)
  and HER2 (ERBB2) negative * Luminal B subtype: Hormone receptor positive (progesterone
  and estrogen) and HER2 (ERBB2) positive  * HER2 positive: Hormone receptor negative
  (progesterone and estrogen) and HER2 (ERBB2) positive * Basal-like or triple-negative
  (TNBCs): Hormone receptor negative (progesterone and estrogen) and HER2 (ERBB2)
  negative  Hormone receptor positive breast cancers are largely driven by the estrogen/ER
  pathway. In HER2 positive breast tumors, HER2 activates the PI3K/AKT and the RAS/RAF/MAPK
  pathways, and stimulate cell growth, survival and differentiation. In patients suffering
  from TNBC, the deregulation of various signaling pathways (Notch and Wnt/beta-catenin),
  EGFR protein have been confirmed. In the case of breast cancer only 8% of all cancers
  are hereditary, a phenomenon linked to genetic changes in BRCA1 or BRCA2. Somatic
  mutations in only three genes (TP53, PIK3CA and GATA3) occurred at >10% incidence
  across all breast cancers.'
last-edited: 2019-11-29
organisms:
- Homo sapiens
redirect_from:
- /index.php/Pathway:WP4262
- /instance/WP4262
schema-jsonld:
- '@context': https://schema.org/
  '@id': https://wikipathways.github.io/pathways/WP4262.html
  '@type': Dataset
  creator:
    '@type': Organization
    name: WikiPathways
  description: 'Breast cancer is the leading cause of cancer death among women worldwide.
    The vast majority of breast cancers are carcinomas that originate from cells lining
    the milk-forming ducts of the mammary gland.   The molecular subtypes of breast
    cancer, which are based on the presence or absence of hormone receptors (estrogen
    and progesterone subtypes) and human epidermal growth factor receptor-2 (HER2),
    include:  * Luminal A subtype: Hormone receptor positive (progesterone and estrogen)
    and HER2 (ERBB2) negative * Luminal B subtype: Hormone receptor positive (progesterone
    and estrogen) and HER2 (ERBB2) positive  * HER2 positive: Hormone receptor negative
    (progesterone and estrogen) and HER2 (ERBB2) positive * Basal-like or triple-negative
    (TNBCs): Hormone receptor negative (progesterone and estrogen) and HER2 (ERBB2)
    negative  Hormone receptor positive breast cancers are largely driven by the estrogen/ER
    pathway. In HER2 positive breast tumors, HER2 activates the PI3K/AKT and the RAS/RAF/MAPK
    pathways, and stimulate cell growth, survival and differentiation. In patients
    suffering from TNBC, the deregulation of various signaling pathways (Notch and
    Wnt/beta-catenin), EGFR protein have been confirmed. In the case of breast cancer
    only 8% of all cancers are hereditary, a phenomenon linked to genetic changes
    in BRCA1 or BRCA2. Somatic mutations in only three genes (TP53, PIK3CA and GATA3)
    occurred at >10% incidence across all breast cancers.'
  keywords:
  - FZD6
  - JUN
  - CDKN1A
  - WNT5A
  - HES1
  - FRAT1
  - WNT16
  - FGF10
  - FZD7
  - RAD50
  - FGF17
  - PARP1
  - WNT4
  - FZD10
  - Notch Signaling
  - IGF1
  - CETN3
  - CCND1
  - FGF9
  - CDK6
  - BAK1
  - MTOR
  - DVL1
  - FGF1
  - AKT3
  - KIT
  - APC
  - '26S Proteasome '
  - NRAS
  - FZD8
  - NBN
  - FZD4
  - BRCA2
  - SOS2
  - MYC
  - Progesterone
  - NOTCH2
  - KRAS
  - DVL2
  - WNT2
  - GRB2
  - HES5
  - POLK
  - BRCA1
  - Cell Cycle
  - SKP1
  - FRAT2
  - FGF2
  - CSNK2A3
  - FZD9
  - LRP6
  - p53 Signaling
  - HEY1
  - FGF16
  - RPS6KB2
  - RB1
  - CDK4
  - RAD51
  - RAF1
  - TCF7L2
  - FGF5
  - WNT7A
  - DLL3
  - WNT10A
  - E2F1
  - 'Wnt Signaling '
  - NCOA3
  - FGF23
  - CSNK1A1L
  - PIK3R3
  - LRP5
  - FGF4
  - DLL1
  - MAP2K2
  - TP53
  - ESR1
  - CSNK2B
  - HEYL
  - BAX
  - FGF8
  - SHC3
  - SHC2
  - DVL3
  - NCOA1
  - FZD1
  - ESR2
  - E2F3
  - RPS6KB1
  - CTNNB1
  - PIK3R1
  - WNT3
  - FOS
  - WNT5B
  - Estrogen Signaling
  - FZD3
  - AKT2
  - EGFR
  - AXIN1
  - APC2
  - GADD45A
  - Pathway
  - WNT2B
  - Angiogenesis
  - FGF20
  - AKT1
  - WNT3A
  - FZD2
  - ERBB2
  - FGF22
  - FGF19
  - PTEN
  - HRAS
  - CSNK2A2
  - LEF1
  - Estrogen
  - DDB2
  - NOTCH3
  - WNT10B
  - FGF6
  - MAPK1
  - 'Cell cycle (G1/S) '
  - NOTCH1
  - Degradation
  - SHC4
  - TCF7L1
  - IGF1R
  - NOTCH4
  - GADD45G
  - GADD45B
  - BRAF
  - PIK3R2
  - progression
  - EGF
  - PIK3CA
  - FLT4
  - MAP2K1
  - ARAF
  - WNT7B
  - NFKB2
  - PIK3CD
  - E2F2
  - TNFSF11
  - MAPK3
  - JAG2
  - FGF7
  - CSNK1A1
  - MRE11A
  - FGF3
  - PIP3
  - SHC1
  - Estradiol-17beta
  - WNT6
  - AXIN2
  - SP1
  - FGF21
  - WNT1
  - TCF7
  - WNT11
  - DLL4
  - FGF18
  - CSNK2A1
  - SOS1
  - FZD5
  - ATM
  - HEY2
  - FGFR1
  - PGR
  - GSK3B
  - ATR
  license: CC0
  name: Breast cancer pathway
seo: CreativeWork
title: Breast cancer pathway
wpid: WP4262
---